Drugs / BNT162b2 (B.1.617.2)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05004181 | Aug 2021 → Aug 2023 | COVID-19, severe acute respiratory syndrome | BioNTech SE | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNT162b2 (B.1.617.2) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05004181 ↗ |